The European Medicines Agency approved Afqlir and Opuviz to treat age-related macular degeneration while reiterating its ...

OPUVIZ™, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen’s second ophthalmology biosimilar to be recommended for marketing authorization by the European Medicines Agency ...

Without widespread access to biosimilars, thousands of cancer patients are losing their battle. Life-saving treatment is not ...

OPUVIZ, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen's second ophthalmology biosimilar to be recommended for marketing authorization by the European Medicines Agency IN ...

HANSIZHUANG ® (serplulimab) was the first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC – ...

Alteogen announced that it has applied for marketing authorization in Korea for ALT-L9, an aflibercept biosimilar ...

A biosimilar, according to the European Medicines Agency (EMA), is a biological medicine that is highly similar to one already approved in the EU. This means patients can expect the same safety and ...

On August 15, 2024, Alvotech and Advanz Pharma announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT06, Alvotech’s biosimilar of low dose ...

EMA advisors at the Committee for Medicinal Products for Human Use (CHMP) recommended Sandoz’s adalimumab Humira biosimilar under three brand names – Halimatoz, Hefiya and Hyrimoz. The firm ...

In terms of its pipeline, the European Medicines Agency ("EMA") has accepted Alvotech's filing for approval for its Eylea biosimilar, AVT06, while a filing for Prolia biosimilar is expected this year.

HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES-  SCLC   - HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 ...

EU rules that all biosimilars are interchangeable The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have, meanwhile, published a statement confirming that all EU ...